Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 16/20 | 0.68 |
| ▸ | KDR | P35968 | 11/20 | 0.64 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.63 |
| ▸ | CDK4 | P11802 | 2/20 | 0.61 |
| ▸ | CCND1 | P24385 | 2/20 | 0.61 |
| ▸ | CCND3 | P30281 | 2/20 | 0.61 |
| ▸ | CDK1 | P06493 | 1/20 | 0.61 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.61 |
| ▸ | CDK2 | P24941 | 1/20 | 0.61 |
| ▸ | LCK | P06239 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3713767 | 1.00 | CHEK1 (0.68) | CHEK1KDRFGFR1CDK4CCND1 | |
| SCHEMBL586321 | 0.87 | TTK (0.64) | CHEK1KDRFGFR1CDK4CCND1 | |
| SCHEMBL586320 | 0.87 | TTK (0.64) | CHEK1KDRFGFR1CDK4CCND1 | |
| SCHEMBL29921084 | 0.87 | TTK (0.64) | CHEK1KDRFGFR1CDK4CCND1 | |
| SCHEMBL3713185 | 0.86 | KDR (0.62) | CHEK1KDRFGFR1CDK4CCND1 | |
| SCHEMBL3713181 | 0.86 | KDR (0.62) | CHEK1KDRFGFR1CDK4CCND1 | |
| SCHEMBL585921 | 0.85 | TTK (0.63) | CHEK1KDRFGFR1CDK4CCND1 | |
| SCHEMBL585920 | 0.85 | TTK (0.63) | CHEK1KDRFGFR1CDK4CCND1 | |
| SCHEMBL3716235 | 0.83 | CHEK1 (0.64) | CHEK1KDRFGFR1CDK2LCK | |
| SCHEMBL3716237 | 0.83 | CHEK1 (0.64) | CHEK1KDRFGFR1CDK2LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8765748-B2 | Indazolyl, benzimidazolyl, benzotriazolyl substituted indolinone derivatives as kinase inhibitors useful in the treatment of cancer | UNIVERSITY HEALTH NETWORK (CA) | 2014-07-01 | — | — | US | disclosed |
| US-20110065702-A1 | INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLINONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | UNIVERSITY HEALTH NETWORK | 2011-03-17 | — | — | US | disclosed |
| CN-101970426-A | Indazolyl-, benzimidazolyl-, benzotriazolyl-substituted indolinone derivatives as kinase inhibitors useful in the treatment of cancer | UNIV HEALTH NETWORK | 2011-02-09 | — | — | CN | disclosed |
| EP-2235004-A1 | INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLMONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | University Health Network (CA) | 2010-10-06 | — | — | EP | disclosed |
| WO-2009079767-A9 | INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLINONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | UNIVERSITY HEALTH NETWORK (CA) | 2009-10-01 | — | — | WO | disclosed |
| WO-2009079767-A1 | INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLINONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | UNIVERSITY HEALTH NETWORK (CA) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065702-A1 | INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLINONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | TNNI3K, ABL1, TK1 | CHEK1 97/4885KDR 679/4885FGFR1 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.